Ascendis Pharma A/S (ASND) vs BridgeBio Pharma (BBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ascendis Pharma A/S (ASND) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 20.1% versus a gain of 11.6%. Over five years, BBIO leads with a +92.2% price change compared with +75.7% for ASND. Ascendis Pharma A/S is the larger company by market cap ($16.58 billion vs $14.81 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | BBIO |
|---|---|---|
| Share price | $252.73 | $76.03 |
| Market cap | $16.58B | $14.81B |
| 1-day change | -1.26% | -2.75% |
| YTD return | +18.52% | -0.60% |
| 1-year return | +20.07% | +11.63% |
| 5-year return | +75.73% | +92.24% |
| P/E ratio (TTM) | 16.62 | — |
| Forward P/E | 20.47 | — |
| EPS (TTM) | $15.21 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $502.08M |
| Revenue growth (YoY) | — | +126.26% |
| Net income (latest FY) | — | $-732.94M |
| Gross margin | — | 95.82% |
| Operating margin | — | -104.25% |
| Net margin | — | -145.98% |
| 52-week high | $282.15 | $93.42 |
| 52-week low | $188.08 | $62.50 |
| Distance from 52-week high | -10.43% | -18.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +24.95% | +40.73% |
| Average volume | 750.65K | 2.67M |
| Shares outstanding | 65.60M | 194.80M |
| Employees | 1,189 | 1,081 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees
ASND vs BBIO FAQ
Which is bigger, Ascendis Pharma A/S or BridgeBio Pharma?
Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $16.58B compared with $14.81B for BridgeBio Pharma (BBIO).
Which stock has performed better over the past year, ASND or BBIO?
ASND returned +20.07% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.
Are Ascendis Pharma A/S and BridgeBio Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.